Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

certolizumab pegol

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of certolizumab pegol

46 trials tracked of certolizumab pegol: 35 in phase 3 or 4 and 11 with published results. The most-cited published study has 181 citations.

46Trials tracked

35Phase 3 & 4

0Recruiting

11With published results

Phase distribution

Phase 4 7 Phase 3 28 Phase 2 7 Phase 1 4

Phase 4 Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate Completed · 181 cited
Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 131 cited
Phase 3 Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Completed · 102 cited
Phase 4 IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA Completed · 73 cited

Show 40 more trials

Phase 3 Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo Completed · 73 cited
Phase 3 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Completed · 50 cited
Phase 4 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Completed · 25 cited
Phase 3 A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis Completed · 21 cited
Phase 4 Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis Completed · 16 cited
Phase 4 A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects Completed
Phase 4 Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines Completed
Phase 4 Dosing Flexibility Study in Patients With Rheumatoid Arthritis Completed
Phase 3 A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis Completed
Phase 3 An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 Completed
Phase 3 Pediatric Arthritis Study of Certolizumab Pegol Completed
Phase 3 Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study Completed
Phase 3 A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Completed
Phase 3 A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Completed
Phase 3 A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease Completed
Phase 3 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis Completed
Phase 3 Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease Completed
Phase 3 Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients Completed
Phase 3 Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease Completed
Phase 3 Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients Completed
Phase 3 Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis Completed
Phase 3 Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) Completed
Phase 3 Mucosal Healing Study in Crohn's Disease (CD) Completed
Phase 3 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis Completed
Phase 3 Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study Completed
Phase 3 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab Completed
Phase 3 Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) Completed
Phase 3 A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Completed
Phase 3 Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease Completed
Phase 2 Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis Completed
Phase 2 Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol Completed
Phase 2 Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease Completed
Phase 2 Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease Completed
Phase 2 A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis Completed
Phase 2 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy Completed
Phase 2 Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668) Completed
Phase 1 A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Completed
Phase 1 A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta Completed
Phase 1 Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test) Completed
Phase 1 A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Completed

Showing the 46 most-cited and recently-updated of 46 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.